The CD52 antigen and development of the CAMPATH antibodies.
Hale
G
G
Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000074301:CD52 Antigen; D015195:Drug Design; D006023:Glycoproteins / Q000037:antagonists & inhibitors* / Q000276:immunology; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects / Q000379:methods*; D007239:Infections / Q000139:chemically induced / Q000276:immunology / Q000503:physiopathology; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D008297:Male; D008322:Mammals / Q000276:immunology; D051381:Rats; D013094:Spermatozoa / Q000276:immunology; D033581:Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; C000613864:Cd52 protein, rat; D006023:Glycoproteins; D000074323:Alemtuzumab